<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537222</url>
  </required_header>
  <id_info>
    <org_study_id>97107155001701</org_study_id>
    <nct_id>NCT03537222</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients With Multiple Myeloma-validation Study</brief_title>
  <official_title>Validation of the Myeloma Patient Outcome Scale (MyPOS) Assessing the Quality of Life in Patients With Multiple Myeloma in the German Speaking Part of Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zurich University of Applied Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantonsspital Münsterlingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Aarau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinik Hirslanden, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zurich University of Applied Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the Myeloma Patient Outcome Scale (MyPOS) will be translated from English to&#xD;
      German. This translated version will be quantitatively and qualitatively validated with&#xD;
      patients with multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with multiple myeloma (N=10) will be interviewed in the qualitative phase about&#xD;
      their comprehension of the translated MyPOS. The questionnaire will be revised according to&#xD;
      the results of the interviews. This culturally adapted Swiss-German MyPOS will be assessed in&#xD;
      the quantitative phase for its' psychometric properties with 200 patients with multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough participants and study funding&#xD;
  </why_stopped>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric properties of the culturally-adapted Swiss-German Myeloma Patient Outcome Scale (MyPOS)</measure>
    <time_frame>upon enrollment</time_frame>
    <description>The primary outcome will be the scores on each item of the culturally-adapted Swiss-German MyPOS. Items are scored on a five-point Likert scale. For the analysis, the three subscales &quot;Symptoms&quot; (range: 0-52), &quot;Emotions&quot; (range:0-68) and &quot;Healthcare Support&quot; (range: 0-12) are assessed as well as the MyPOS total score (range: 0-132 ) by summing up the item scores ranging from 0-4. Higher scores reflect worse quality of life.&#xD;
The scores will be used to evaluate the psychometric properties of the culturally-adapted Swiss-German MyPOS:&#xD;
Structural validity,&#xD;
Internal consistency,&#xD;
Construct validity,&#xD;
Convergent and divergent validity.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">58</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>MyPOS</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Myeloma Patient Outcome Scale (MyPOS)</intervention_name>
    <description>Patients complete the MyPOS questionnaire on quality of life</description>
    <arm_group_label>MyPOS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with multiple myeloma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent as documented by signature&#xD;
&#xD;
          -  confirmed histological diagnosis of multiple myeloma,&#xD;
&#xD;
          -  age ≥ 18 years,&#xD;
&#xD;
          -  mental capacity to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to communicate in German&#xD;
&#xD;
          -  participation in another clinical study&#xD;
&#xD;
          -  more than one cancer diagnosis&#xD;
&#xD;
          -  mental illness (i.e. psychiatric diagnosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Julia Dratva, Prof.Dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zurich University of Applied Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Münsterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <state>Thurgau</state>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Zurich</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zurich University of Applied Sciences</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Julia Dratva</investigator_full_name>
    <investigator_title>Head of health sciences research unit</investigator_title>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>psychometrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

